Comparison:Article Title: Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial
Article Snippet: .. Median morning Cortisol (Safety Set) p-value: paired t-test for within group comparison 7/7 Table, not cited: Study Efficacy Endpoints Study endpoints Reported Co-primary endpoint Clinical remission, mucosal healing X Secondary endpoints Clinical remission and mucosal healing (within-patient combination of both components) X Deepened mucosal healing X Deepened clinical remission X Clinical remission; deepened mucosal healing (within-patient combination) Deepened clinical remission, deepened mucosal healing (within-patient combination) X Time to clinical symptom resolution X Time to first clinical remission according to Löfberg Time to resolution of the hallmark symptoms of ulcerative proctitis Change of total modified UC-DAI Change in clinical symptoms (rectal bleeding and stool frequency) Change in endoscopic (mucosal) appearance Change in physician's rating of disease activity Individual items of modified UC-DAI in the course of the trial Change in UCEIS Change in histological assessment scores (Riley index) Histological improvement based on Riley’s histological index Change of erythrocyte sedimentation rate Course of faecal calprotectin Patient’s acceptance of treatment X Patient’s preference of formulation X Physician’s global assessment X Short Health Scale X Work Productivity and Activity Impairment X Exploratory endpoints - mesalazine non-responders Clinical remission X Mucosal healing X Clinical remission, mucosal healing (within-patient combination) X ..
Modification:Article Title: Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial
Article Snippet: .. Median morning Cortisol (Safety Set) p-value: paired t-test for within group comparison 7/7 Table, not cited: Study Efficacy Endpoints Study endpoints Reported Co-primary endpoint Clinical remission, mucosal healing X Secondary endpoints Clinical remission and mucosal healing (within-patient combination of both components) X Deepened mucosal healing X Deepened clinical remission X Clinical remission; deepened mucosal healing (within-patient combination) Deepened clinical remission, deepened mucosal healing (within-patient combination) X Time to clinical symptom resolution X Time to first clinical remission according to Löfberg Time to resolution of the hallmark symptoms of ulcerative proctitis Change of total modified UC-DAI Change in clinical symptoms (rectal bleeding and stool frequency) Change in endoscopic (mucosal) appearance Change in physician's rating of disease activity Individual items of modified UC-DAI in the course of the trial Change in UCEIS Change in histological assessment scores (Riley index) Histological improvement based on Riley’s histological index Change of erythrocyte sedimentation rate Course of faecal calprotectin Patient’s acceptance of treatment X Patient’s preference of formulation X Physician’s global assessment X Short Health Scale X Work Productivity and Activity Impairment X Exploratory endpoints - mesalazine non-responders Clinical remission X Mucosal healing X Clinical remission, mucosal healing (within-patient combination) X ..
Activity Assay:Article Title: Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial
Article Snippet: .. Median morning Cortisol (Safety Set) p-value: paired t-test for within group comparison 7/7 Table, not cited: Study Efficacy Endpoints Study endpoints Reported Co-primary endpoint Clinical remission, mucosal healing X Secondary endpoints Clinical remission and mucosal healing (within-patient combination of both components) X Deepened mucosal healing X Deepened clinical remission X Clinical remission; deepened mucosal healing (within-patient combination) Deepened clinical remission, deepened mucosal healing (within-patient combination) X Time to clinical symptom resolution X Time to first clinical remission according to Löfberg Time to resolution of the hallmark symptoms of ulcerative proctitis Change of total modified UC-DAI Change in clinical symptoms (rectal bleeding and stool frequency) Change in endoscopic (mucosal) appearance Change in physician's rating of disease activity Individual items of modified UC-DAI in the course of the trial Change in UCEIS Change in histological assessment scores (Riley index) Histological improvement based on Riley’s histological index Change of erythrocyte sedimentation rate Course of faecal calprotectin Patient’s acceptance of treatment X Patient’s preference of formulation X Physician’s global assessment X Short Health Scale X Work Productivity and Activity Impairment X Exploratory endpoints - mesalazine non-responders Clinical remission X Mucosal healing X Clinical remission, mucosal healing (within-patient combination) X ..
Sedimentation:Article Title: Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial
Article Snippet: .. Median morning Cortisol (Safety Set) p-value: paired t-test for within group comparison 7/7 Table, not cited: Study Efficacy Endpoints Study endpoints Reported Co-primary endpoint Clinical remission, mucosal healing X Secondary endpoints Clinical remission and mucosal healing (within-patient combination of both components) X Deepened mucosal healing X Deepened clinical remission X Clinical remission; deepened mucosal healing (within-patient combination) Deepened clinical remission, deepened mucosal healing (within-patient combination) X Time to clinical symptom resolution X Time to first clinical remission according to Löfberg Time to resolution of the hallmark symptoms of ulcerative proctitis Change of total modified UC-DAI Change in clinical symptoms (rectal bleeding and stool frequency) Change in endoscopic (mucosal) appearance Change in physician's rating of disease activity Individual items of modified UC-DAI in the course of the trial Change in UCEIS Change in histological assessment scores (Riley index) Histological improvement based on Riley’s histological index Change of erythrocyte sedimentation rate Course of faecal calprotectin Patient’s acceptance of treatment X Patient’s preference of formulation X Physician’s global assessment X Short Health Scale X Work Productivity and Activity Impairment X Exploratory endpoints - mesalazine non-responders Clinical remission X Mucosal healing X Clinical remission, mucosal healing (within-patient combination) X ..
Formulation:Article Title: Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial
Article Snippet: .. Median morning Cortisol (Safety Set) p-value: paired t-test for within group comparison 7/7 Table, not cited: Study Efficacy Endpoints Study endpoints Reported Co-primary endpoint Clinical remission, mucosal healing X Secondary endpoints Clinical remission and mucosal healing (within-patient combination of both components) X Deepened mucosal healing X Deepened clinical remission X Clinical remission; deepened mucosal healing (within-patient combination) Deepened clinical remission, deepened mucosal healing (within-patient combination) X Time to clinical symptom resolution X Time to first clinical remission according to Löfberg Time to resolution of the hallmark symptoms of ulcerative proctitis Change of total modified UC-DAI Change in clinical symptoms (rectal bleeding and stool frequency) Change in endoscopic (mucosal) appearance Change in physician's rating of disease activity Individual items of modified UC-DAI in the course of the trial Change in UCEIS Change in histological assessment scores (Riley index) Histological improvement based on Riley’s histological index Change of erythrocyte sedimentation rate Course of faecal calprotectin Patient’s acceptance of treatment X Patient’s preference of formulation X Physician’s global assessment X Short Health Scale X Work Productivity and Activity Impairment X Exploratory endpoints - mesalazine non-responders Clinical remission X Mucosal healing X Clinical remission, mucosal healing (within-patient combination) X ..
|
